ID
45412
Beschreibung
Principal Investigator: Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA MeSH: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000548 The study protocol for both cohorts has been previously described (Journal of Thrombosis and Thrombolysis 2012:1-12). HV1 cohort: Briefly 50 healthy volunteers were exposed to two weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by microarray before and after aspirin exposure. The pre-aspirin samples were profiled on the U133A 2.0 array and the post-aspirin samples were profiled on the U1333plus 2.0 array. HV2 cohort: Briefly 53 healthy volunteers were exposed to four weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by U133plus 2.0 array before and after aspirin exposure.
Link
Stichworte
Versionen (1)
- 20.11.22 20.11.22 - Chiara Middel
Rechteinhaber
Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA
Hochgeladen am
20. November 2022
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs000548 Aspirin Pharmacogenomics
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
Ähnliche Modelle
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
C0680251 (UMLS CUI [1,2])
C1552738 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])